Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer

Urology

Volumn 76, Issue 5, 2010, Pages 1189-1193

  Lodde, Michele ^a   Lacombe, Louis ^a   Fradet, Yves ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CASTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SALVAGE THERAPY; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; CASTRATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; SURVIVAL RATE; TOSYL COMPOUNDS;

EID: 78149295955     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.12.057     Document Type: Article

References (20)

1. A. Jemal, T. Murray, and A. Samuels Cancer statistics, 2003 CA Cancer J Clin 53 2003 5 26
2. P. Boyle, and J. Ferlay Cancer incidence and mortality in Europe, 2004 Ann Oncol 16 2005 481 488
3. J.L. Mohler, C.W. Gregory, and O.H. Ford 3rd The androgen axis in recurrent prostate cancer Clin Cancer Res 10 2004 440 448
4. J.A. Locke, C.C. Nelson, and H.H. Adomat Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts J Steroid Biochem Mol Biol 115 2009 126 136
5. M. Stanbrough, G.J. Bubley, and K. Ross Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
6. J.L. Mohler Castration-recurrent prostate cancer is not androgen-independent Adv Exp Med Biol 617 2008 223 234
7. H.I. Scher, C. Liebertz, and W.K. Kelly Bicalutamide for advanced prostate cancer: the natural versus treated history of disease J Clin Oncol 15 1997 2928 2938
8. R. Joyce, M.A. Fenton, and P. Rode High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy J Urol 159 1998 149 153
9. O. Kucuk, E. Fisher, and C.M. Moinpour Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235) Urology 58 2001 53 58
10. H. Suzuki, K. Okihara, and H. Miyake Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade J Urol 180 2008 921 927
11. J.D. Debes, and D.J. Tindall Mechanisms of androgen-refractory prostate cancer N Engl J Med 351 2004 1488 1490
12. K. Haapala, T. Kuukasjarvi, and E. Hyytinen Androgen receptor amplification is associated with increased cell proliferation in prostate cancer Hum Pathol 38 2007 474 478
13. A. Hobisch, A. Fritzer, and B. Comuzzi The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide Prostate 66 2006 413 420
14. J.A. Ruizeveld de Winter, P.J. Janssen, and H.M. Sleddens Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer Am J Pathol 144 1994 735 746
15. M.A. Titus, M.J. Schell, and F.B. Lih Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clin Cancer Res 11 2005 4653 4657
16. G. Attard, A.H. Reid, and T.A. Yap Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
17. J.S. Lam, J.T. Leppert, and S.N. Vemulapalli Secondary hormonal therapy for advanced prostate cancer J Urol 175 2006 27 34
18. F.J. Debruyne, R. Murray, and Y. Fradet Liarozolea novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate Liarozole Study Group Urology 52 1998 72 81
19. I.M. Thompson, C. Tangen, and J. Basler Impact of previous local treatment for prostate cancer on subsequent metastatic disease J Urol 168 2002 1008 1012
20. M.R. Smith, F. Kabbinavar, and F. Saad Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 23 2005 2918 2925